Iovance Biotherapeutics (IOVA) 10-Q2013 Q1 Quarterly report

Filed: 23 Oct 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: add, advertisement, appointed, appointing, appointment, blank, bore, bridge, Bristol, cancellation, carryforward, check, Clarifying, concurrently, contemplated, cumulative, David, Delaware, Derecognition, disinterested, disseminated, diversity, earliest, eliminate, evidenced, expert, explained, explicit, extent, extinguished, fifty, fill, forfeited, found, fullest, Handelman, higher, Hillsberg, hold, holding, hundred, indemnification, Jay, Kessler, lion, Manish, Martin, Matrix, maximum, McPeak, Merrill, Michael, mutual, opt, ownership, par, Parent, pari, Paul, penalty, PIPE, preferred, proforma, prosecution, receipt, reconstitute, reflect, reinvested, removed, replace, Repricing, request, resignation, resigned, restated, restructuring, retroactively, SAB, salary, Sanford, Scope, serve, Singh, solicitation, source, specialist, Stephen, thereon, translation, unamortized, unchanged, underwent, unrecognized, vacancy, Venkatesan, virtually, voluntarily, Voyticky, widely, William

Removed: acceleration, accept, accompany, adequate, AICPA, allocate, anytime, arrangement, assessment, assure, automatic, bankruptcy, biological, Black, Blvd, breach, California, called, Certification, chemical, closed, committed, comply, conceived, conference, confidence, consecutive, Contego, contract, convert, country, cured, curtail, customary, daily, dedicated, deducted, delivery, designing, disclose, discontinue, dividend, duly, Emerging, encourage, equipment, event, exceeded, excluding, execute, expand, expiration, expire, expiring, explore, exposed, exposure, extend, extension, facility, fact, fail, failure, fit, flow, foreclose, foreclosure, foreseeable, generation, GMP, Good, goodwill, government, growth, healthcare, hierarchy, hired, holder, implemented, implementing, improve, improved, industry, insolvency, institutional, intelligent, Intent, invented, investigate, involved, involving, Kestrel, laboratory, leading, lease, lethal, Letter, listed, LOI, Los, lose, maintain, marketable, matured, nature, negative, objective, office, Olympic, online, operate, optimizing, outsource, parking, parri, perform, prepaid, preparative, prepay, preserve, prevent, primary, principally, priority, production, profitability, promulgated, proper, purpose, qualitative, reactivity, real, recapitalization, recent, recently, registrant, remedial, remedy, rent, reorganization, reservation, Reserve, retrospectively, science, selected, selection, sell, sensitivity, set, sharing, significantly, Specifically, spend, standard, statutory, step, strike, sublicense, suitable, Suite, supplier, system, Task, Testing, Theorem, thereunto, Tranche, treating, turn, twenty, unable, underserved, undersigned, understand, unit, unwritten, utilized, varied, vitro, volume, waive, waived, Westwood, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IOVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Lion Biotechnologies, Inc. (the “Company”) for the quarter ended March 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Manish Singh, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 22, 2013	By:	/s/ Manish Singh
		Manish Singh
		Chief Executive Officer

This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.